Eva-based transdermal matrix system for the administration of an estrogen and/or a progestogen
US5605702A · kind A · utility
Assignee
Inventors
Key dates
| Filing date | Mar 28, 1995 |
| Grant date | Feb 25, 1997 |
| Priority date | — |
| Expiry date | Mar 28, 2015 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P5/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a new self-adhesive transdermal matrix system for the administration of a hormone by percutaneous route, said system which comprises a support and self-adhesive matrix, having a matrix comprising: PA1 (a) 40 to 60 parts by weight of an ethylene/vinyl acetate copolymer, PA1 (b) 5 to 20 parts by weight of a cellulosic material, PA1 (c) 35 to 55 parts by weight of at least one compound selected from the group consisting of: crotamiton, N-substituted 2-pyrrolidones of the formula I, ##STR1## in which the R group represents a (C.sub.1 -C.sub.15)-alkyl, cyclohexyl or 2-hydroxyethyl group, and higher C.sub.12 -C.sub.20 aliphatic alcohols, and PA1 (d) 0,01 to 7 parts by weight of a hormone selected from the group consisting of estrogen components, progestogen components and mixtures thereof. It also relates to a method for preparing this transdermal matrix system.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.